MDM4 is a key therapeutic target in cutaneous melanoma

Gembarska, Agnieszka, Luciani, Flavie, Fedele, Clare, Russell, Elisabeth A, Dewaele, Michael, Villar, Stéphanie, Zwolinska, Aleksandra, Haupt, Sue +14 more·2012·Nature Medicine

DOI 10.1038/nm.2863

Cited by (330)

Items 101–200 of 330

MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response
Francesca Romana Mancini, Luisa Pieroni, Valentina Monteleone, Rossella Lucà, Laura Fici, Emilia Luca, Andrea Urbani, Shunbin Xiong, Silvia Soddu, Riccardo Masetti et al. · 2015 · Oncogene
p53 Requires the Stress Sensor USF1 to Direct Appropriate Cell Fate Decision
Amine Bouafia, Sébastien Corre, David Gilot, Nicolas Mouchet, Sharon Prince, Marie‐Dominique Galibert · 2014 · PLoS Genetics
Reactivation of p53 as therapeutic intervention for malignant melanoma
Aart G. Jochemsen · 2013 · Current Opinion in Oncology
Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy
Min M. Lu, Paul F. Miller, Xin Lü · 2014 · FEBS Letters
Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays
Ban Xiong Tan, Christopher John Brown, Fernando Jose Ferrer, Tsz Ying Yuen, Soo Tng Quah, Boon Hong Chan, Anna Elisabet Jansson, Hsiangling Teo, Pär Nordlund, David Philip Lane · 2015 · Scientific Reports
Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Zhenyu Ji, Raj Kumar, Michael Taylor, Anpuchchelvi Rajadurai, Alexander Marzuka-Alcalá, Yiyin Erin Chen, Ching-Ni Jenny Njauw, Keith T. Flaherty, Goran G. Jonsson, Hensin Tsao · 2013 · Clinical Cancer Research
AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex
Anna de Polo, Zhongling Luo, Casimiro Gerarduzzi, Xiang Chen, John B. Little, Zhi-Min Yuan · 2016 · Journal of Molecular Cell Biology
Anatomy of Mdm2 and Mdm4 in evolution
Ban Xiong Tan, Hoe Peng Liew, Joy Shijia Chua, Farid John Ghadessy, Yaw Sing Tan, David Philip Lane, Cynthia R. Coffill · 2017 · Journal of Molecular Cell Biology
Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
Alessandra Monti, Luigi Vitagliano, Andrea Caporale, Menotti Ruvo, Nunzianna Doti · 2023 · International Journal of Molecular Sciences
MDM4 is a rational target for treating breast cancers with mutant p53
Panimaya Jeffreena Miranda, D Buckley, Dinesh Raghu, Jia‐Min Pang, Elena A. Takano, Reshma Vijayakumaran, Amina F.A.S. Teunisse, Atara Posner, Tahlia Procter, Marco J. Herold et al. · 2017 · The Journal of Pathology
PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA
Kimiyoshi Yano, Ryou‐u Takahashi, Bunsyo Shiotani, Junko Abe, Tomoki Shidooka, Yuki Sudo, Yusuke Yamamoto, Shisei Kan, Hiroki Sakagami, Hidetoshi Tahara · 2021 · Journal of Biological Chemistry
Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity
Boris Bardot, Rachida Bouarich-Bourimi, Julia Leemput, Vincent Lejour, Annaïg Hamon, L Plancke, Aart G. Jochemsen, Iva Simeonova, M Fang, Franck Toledo · 2014 · Oncogene
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study
Karim M. ElSawy, Chandra Shekhar Verma, Thomas Leonard Joseph, David Philip Lane, Reidun Twarock, Leo S. D. Caves · 2013 · Cell Cycle
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
Jennifer Hüllein, Mikolaj Michal Slabicki, Maciej Rosołowski, Alexander Jethwa, Stefan Habringer, Katarzyna Tomska, Roma Kurilov, Junyan Lu, Sebastian Scheinost, Rabea Wagener et al. · 2019 · Cancer Research
Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation
Prithi Raguraman, Akilandeswari Ashwini Balachandran, Suxiang Chen, Sarah D. Diermeier, Rakesh Naduvile Veedu · 2021 · Cancers
Dominant Effects of Δ40p53 on p53 Function and Melanoma Cell Fate
Rie Takahashi, Svetomir N. Markovic, Heidi J. Scrable · 2013 · Journal of Investigative Dermatology
Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma
Michael Olvedy, Julie C. Tisserand, Flavie Luciani, Bram Boeckx, Jasper Wouters, Sophie Lopez, Florian Rambow, Sara Aibar, Bernard Thienpont, Jasmine Barra et al. · 2017 · Journal of Clinical Investigation
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
Ban Xiong Tan, Kian Hoe Khoo, Tit Meng Lim, David Philip Lane · 2013 · Oncotarget
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Monika Štětková, Kateřina Growková, Petr Fojtík, Barbora Valčíková, Veronika Palušová, Amandine Verlande, Radek Jorda, Vladimı́r Kryštof, Václav Hejret, Panagiotis Alexiou et al. · 2020 · Cell Death and Disease
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
Zuzana Mrkvová, Stjepan Uldrijan, Antonio R. Pombinho, Petr Bartůněk, Iva Slaninová · 2019 · Molecules
Long Non-coding RNA SNHG12 Functions as a Competing Endogenous RNA to Regulate MDM4 Expression by Sponging miR-129-5p in Clear Cell Renal Cell Carcinoma
Zhipeng Wu, Dongming Chen, Kai Wang, Changchun Cao, Xianlin Xu · 2019 · Frontiers in Oncology
p53 Family in Resistance to Targeted Therapy of Melanoma
Ignacija Vlašić, Anđela Horvat, Ana Tadijan, Neda Slade · 2022 · International Journal of Molecular Sciences
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells
Marijke C.C. Sachweh, William C. Stafford, Catherine J. Drummond, Anna R. McCarthy, Maureen Higgins, Johanna Campbell, Bertha A. Brodin, Elias S.J. Arnér, Sonia Laı́n · 2015 · Oncotarget
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis
Shunbin Xiong, Vinod Pant, Yun Zhang, Neeraj K. Aryal, Mingjian James You, Donna F. Kusewitt, Guillermina Lozano · 2016 · The Journal of Pathology
Genetics of melanoma
Janet Wangari‐Talbot, Suzie Chen · 2013 · Frontiers in Genetics
Delivery of proteins encapsulated in chitosan-tripolyphosphate nanoparticles to human skin melanoma cells
Mai Bay Stie, Henrik Seir Thoke, Olaf‐Georg Issinger, Jennifer Hochscherf, Bárbara Guerra, Lars Folke Olsen · 2018 · Colloids and Surfaces B Biointerfaces
New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions
Ahmad Najem, Mohammad Krayem, Anne Perdrix, Joseph N. Kerger, Ahmad Hussein Awada, Fabrice Journé, Ghanem Ghanem · 2017 · Anticancer Research
Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
Karam Khaddour, Lucas Maahs, Ana Maria Avila Rodriguez, Yazan Maamar, Sami Samaan, George Ansstas · 2021 · Cancers
Targeting WEE1/AKT Restores p53-Dependent Natural Killer–Cell Activation to Induce Immune Checkpoint Blockade Responses in “Cold” Melanoma
Saketh Sriram Dinavahi, Yu‐Chi Chen, Kishore Punnath, Arthur S Berg, Meenhard Herlyn, Momeneh Foroutan, Nicholas D. Huntington, Gavin P. Robertson · 2022 · Cancer Immunology Research
NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation
Takeshi Namiki, Tomonori Yaguchi, Kenta Nakamura, Julio C. Valencia, Sergio G. Coelho, Lanlan Yin, Masakazu Kawaguchi, Wilfred D. Vieira, Yasuhiko Kaneko, Atsushi Tanemura et al. · 2015 · Cancer Research
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
Ilaria Penna, Alessandra Molla, Giulia Grazia, Loredana Cleris, Gabriella Nicolini, Federica Perrone, Benedetta Picciani, Michele Del Vecchio, Filippo de Braud, Roberta Mortarini et al. · 2015 · Oncotarget
MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer.
Hong Yan, Xiaoying Chen, Yu Li, Lei Fan, Yusi Tai, Yang Zhou, Yuxiang Chen, Xinming Qi, Ruimin Huang, Jin Ren · 2019 · Europe PMC (PubMed Central)
Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
Liren Jiang, Natasha Malik, Pilar Acedo, Joanna Zawacka‐Pankau · 2019 · Cell Death Discovery
From Tank to Treatment: Modeling Melanoma in Zebrafish
William Tyler Frantz, Craig J. Ceol · 2020 · Cells
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells
Shiyan Zhang, Ziqin Yan, Yafang Li, Yang Gong, Xilin Lyu, Jianfeng Lou, Daizhou Zhang, Xiangjing Meng, Yujun Zhao · 2022 · Journal of Medicinal Chemistry
p53 binds the mdmx mRNA and controls its translation
A-S Tournillon, Ignacio López, Laurence Malbert-Colas, Sarah Findakly, Nadia Naski, Vanesa Olivares‐Illana, Konstantinos Karakostis, Bořivoj Vojtěšek, Karin Nylander, Robin Fåhræus · 2016 · Oncogene
A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
Georgios Valianatos, Barbora Valčíková, Kateřina Growková, Amandine Verlande, Jitka Mlčochová, Lenka Radová, Monika Štětková, Michaela Vyhnakova, Ondřej Slabý, Stjepan Uldrijan · 2017 · PLoS ONE
Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance
Joana B. Loureiro, Liliana Raimundo, Juliana Calheiros, Carla S. C. Carvalho, Valentina Barcherini, Nuno R. Lima, Célia M. F. Gomes, Maria Inês Almeida, Marco Gouveia Alves, José Luís Costa et al. · 2021 · Cancers
Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness
Ana Tadijan, Francesca Precazzini, Nikolina Hanžić, Martina Radić, Nicolò Gavioli, Ignacija Vlašić, Petar Ozretić, Lia Pinto, Lidija Škreblin, Giulia Barban et al. · 2021 · Cancers
DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma
Sandra J. Pavey, Loredana Spoerri, Nikolas K. Haass, Brian G. Gabrielli · 2013 · Pigment Cell & Melanoma Research
Prognostic and predictive biomarkers in melanoma: an update
Mona Foth, Jasper Wouters, C. de Chaumont, Peter Dynoodt, William M. Gallagher · 2015 · Expert Review of Molecular Diagnostics
Salvation of the fallen angel: Reactivating mutant p53
Li Yang, Zhuoyi Wang, Yuchen Chen, Robert B. Petersen, Ling Zheng, Kun Huang · 2019 · British Journal of Pharmacology
Therapeutic Strategies to Activate p53
Angelo Aguilar, Shaomeng Wang · 2022 · Pharmaceuticals
Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions
Tim J. Blackburn, Shafiq Uddin Ahmed, Christopher R. Coxon, Junfeng Liu, Xiaohong Lü, Bernard T. Golding, Roger J. Griffin, Claire Hutton, David R. Newell, O. Stephen Ojo et al. · 2013 · MedChemComm
Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy
Wendy Delbart, Jirair Karabet, Gwennaëlle Marin, Sébastien Penninckx, Jonathan Derrien, Ghanem Ghanem, Patrick Flamen, Zéna Wimana · 2022 · International Journal of Molecular Sciences
Molecular background of skin melanoma development and progression: therapeutic implications
Magdalena Olbryt · 2019 · Advances in Dermatology and Allergology
Mdm4 supports DNA replication in a p53-independent fashion
Kai Wohlberedt, Ina Klusmann, Polina K. Derevyanko, Kester Mo Henningsen, Josephine Ann Mun Yee Choo, Valentina Manzini, Anna Magerhans, Celeste Giansanti, Christine M. Eischen, Aart G. Jochemsen et al. · 2020 · Oncogene
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Salès, Fabrice Journe, Ahmad Hussein Awada, Ghanem Ghanem et al. · 2019 · Cancers
Mdm2 protein Expression is Strongly Associated with Survival in Malignant Pleural Mesothelioma
Fabian Dominik Mairinger, Robert F. H. Walter, Saskia C. Ting, Claudia Vollbrecht, Jens Kollmeier, S Griff, Thomas Hager, Thomas Mairinger, Daniel Christian Christoph, Dirk Theegarten et al. · 2014 · Future Oncology
Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM 4 and MDM 2 in colon and gastric cancer cells
Mamiko Imanishi, Yoshiyuki Yamamoto, Xiaoxuan Wang, Akinori Sugaya, Mitsuaki Hirose, Shinji Endo, Yukikazu Natori, Kenji Yamato, Ichinosuke Hyodo · 2018 · Cancer Science
Nevi, dysplastic nevi, and melanoma
Wei‐Wen Sung, Chung‐Hsing Chang · 2021 · Tzu Chi Medical Journal
Peli1 Modulates the Subcellular Localization and Activity of Mdmx
Dawei Li, Omid Tavana, Shao‐Cong Sun, Wei Gu · 2018 · Cancer Research
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma
Lan Cao, Ahmed Basudan, Matthew J. Sikora, Amir Bahreini, Nilgun Tasdemir, Kevin M. Levine, Rachel Catherine Jankowitz, Priscilla F. McAuliffe, David J. Dabbs, Sue Haupt et al. · 2019 · Cancer Letters
XI-006 induces potent p53-independent apoptosis in Ewing sarcoma
Kathleen I. Pishas, Alaknanda Adwal, Susan J. Neuhaus, Mark Clayer, Gelareh Farshid, Alexander H. Staudacher, David Frederick Callen · 2015 · Scientific Reports
p53: from understanding its structure to advances in therapeutic targeting
Wenhua Wang, Xia Liu, Hengqi Liu, Hassan Abolhassani, Han Yan, Huilai Zhang, Xianhuo Wang · 2026 · Signal Transduction and Targeted Therapy
Human relevance of NRAS/BRAF mouse melanoma models
Alejandro Conde‐Perez, Lionel Larue · 2013 · European Journal of Cell Biology
A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes
Sreeja Sarojini, Andrew L. Pecora, Natasha Milinovikj, Joseph C. Barbiere, Saakshi Gupta, Zeenathual M. Hussain, Mehmet Yakup Tuna, Jennifer Bo Jiang, Laura Adrianzen, Jaewook Jun et al. · 2015 · Melanoma Research
Genomic aberrations of MDM 2, MDM 4, FGFR 1 and FGFR 3 are associated with poor outcome in patients with salivary gland cancer
Tobias Ach, Stephan Schwarz‐Furlan, Stephanie Ach, Abbas Agaimy, Michael Gerken, Christian Rohrmeier, Johannes Zenk, Heinrich Iro, Gero Brockhoff, Tobias Ettl · 2015 · Journal of Oral Pathology and Medicine
p53 targets TSPAN8 to prevent invasion in melanoma cells
Gweltaz Agaësse, Laetitia Barbollat‐Boutrand, Manale El Kharbili, Odile Berthier‐Vergnes, Ingrid Masse · 2017 · Oncogenesis
Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling
Mathias Luidor Heltberg, Sheng‐hong Chen, Alba Jiménez, Ashwini Jambhekar, Mogens H. Jensen, Galit Lahav · 2019 · Cell Systems
Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles
Lixian Oh, Pierre L. Hainaut, Sandrine Blanchet, Hany Ariffin · 2020 · BMC Cancer
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
Jing Cheng, Ziqin Yan, Kailong Jiang, Chen Liu, Dehua Xu, Xilin Lyu, Xiaobei Hu, Shiyan Zhang, Yubo Zhou, Jia Li et al. · 2023 · Journal of Medicinal Chemistry
Targeting MDM4 Splicing in Cancers
Boris Bardot, Franck Toledo · 2017 · Genes
Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
Ankit A. Patel, Lucía Fraile García, Viviana Mannella, Luke Gammon, Tiffanie‐Marie Borg, Tania Maffucci, Maria Scatolini, Giovanna Chiorino, Elisabetta Vergani, Monica Rodolfo et al. · 2020 · Cancer Research
The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma
Chi–Che Hsieh, Che‐Hung Shen · 2019 · Current Treatment Options in Oncology
Two-Dimensional Borocarbonitride Nanosheet-Engineered Hydrogel as an All-In-One Platform for Melanoma Therapy and Skin Regeneration
Cancan Zhao, Jianyu Wan, Liangzhu Zhang, Chen Zhang, Jiemin Wang, Kaili Lin, Xudong Wang · 2022 · Chemistry of Materials
High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Xin Han, Leonard Jeffrey Medeiros, Yu Helen Zhang, Mingjian James You, Michael Andreeff, Marina Y Konopleva, Carlos Bueso-Ramos · 2016 · Clinical Lymphoma Myeloma & Leukemia
Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex
Gerarduzzi, Casimiro, de Polo, Anna, Liu, Xue-Song, El Kharbili, Manale, Little, John B., Yuan, Zhi-Min · 2016 · Journal of Biological Chemistry
Recent advances in radiosensitivity determinants in melanoma
Mohammad Krayem, Ghanem E. Ghanem, Dirk Van Gestel · 2022 · Current Opinion in Oncology
MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Jin Wu, Guanting Lu, Xinjiang Wang · 2021 · PubMed Central
The Cross Talk between Cellular Senescence and Melanoma: From Molecular Pathogenesis to Target Therapies
Jiahua Liu, Runzi Zheng, Yanghuan Zhang, Shuting Jia, Yonghan He, Jing Liu · 2023 · Cancers
Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis
Leiwei Jiang, Shibo Huang, Jieqiong Wang, Yiwei Zhang, Yuqing Xiong, Shelya X. Zeng, Hua Lu · 2020 · Cell Death and Disease
BRN2 is a non-canonical melanoma tumor-suppressor
Michael Hamm, Pierre Sohier, Valérie Petit, Jérémy H. Raymond, Véronique Delmas, Madeleine Le Coz, Franck Gesbert, Colin Kenny, Zackie Aktary, Marie Pouteaux et al. · 2021 · Nature Communications
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy
Robert F. H. Walter, Claudia Vollbrecht, Robert Werner, Thomas Mairinger, Jan Schmeller, Elena Flom, Jeremias Wohlschlaeger, Nikolaos G. Barbetakis, Dimitrios Paliouras, Fotios G. Chatzinikolaou et al. · 2016 · Journal of Cancer
New Anticancer Agents Mimicking Protein Recognition Motifs
Marco Persico, Anna Ramunno, Vita Maglio, Silvia Franceschelli, Chiara Esposito, Alfonso Carotenuto, Diego Brancaccio, Valeria De Pasquale, Luigi Michele Pavone, Michela Varra et al. · 2013 · Journal of Medicinal Chemistry
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies
Renier C. Heijkants, Maaike C. Nieveen, K. C.’t Hart, Amina F.A.S. Teunisse, Aart G. Jochemsen · 2018 · Oncogenesis
Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5
Pu Wang, Yucheng Lu, Yuan Fei Li, Lan Wang, Shao Chin Lee · 2018 · Journal of Diabetes Research
Suppressor of cytokine signalling‐1 induces significant preclinical antitumor effect in malignant melanoma cells
Naoko Tagami‐Nagata, Satoshi Serada, Minoru Fujimoto, Atsushi Tanemura, Rie Nakatsuka, Tomoharu Ohkawara, Hiroyuki Murota, Tadamitsu Kishimoto, Ichiro Katayama, Tetsuji Naka · 2015 · Experimental Dermatology
Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction
Nasim Rasafar, Abolfazl Barzegar, Elnaz Mehdizadeh Aghdam · 2020 · Scientific Reports
Developing melanoma therapeutics: overview and update
John B. Korman, David E. Fisher · 2013 · WIREs Systems Biology and Medicine
RNPS1 functions as an oncogenic splicing factor in cervical cancer cells
Bhagyashree Deka, Pratap Chandra, Priyanka Yadav, Ayushi Rehman, Sweta Kumari, Ajaikumar Bahulayan Kunnumakkara, Kusum Kumari Singh · 2022 · IUBMB Life
Machine learning modeling and prognostic value analysis of invasion-related genes in cutaneous melanoma
Enyu Yang, Qianyun Ding, Xiaowei Fan, Haihan Ye, Cheng Xuan, Shuo Zhao, Qing Ji, Weihua Yu, Yongfu Liu, Jun Cao et al. · 2023 · Computers in Biology and Medicine
p53–MDM2 and MDMX Antagonists
Constantinos G. Neochoritis, Natalia Estrada‐Ortiz, Kareem Khoury, Alexander S. S. Dömling · 2014 · Annual reports in medicinal chemistry
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
Lin Wu, Yuxiang Yan, Qingling Huang, Dali Zheng · 2024 · Biologics
Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
Julija Mozūraitienė, Kristina Bielskienė, Vydmantas Atkočius, Danutė Labeikytė · 2015 · Medicina
Cross-species analysis of melanoma enhancer logic using deep learning
Liesbeth Minnoye, Ibrahim Ihsan Taskiran, David Mauduit, Maurizio Fazio, Linde Van Aerschot, Gert Hulsemans, Valerie Christiaens, Samira Makhzami, Monika Heidemarie Seltenhammer, Panagiotis Karras et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date
C. Lemech, J. Infante, H. Arkenau · 2013 · Drugs
Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation
Xiaolei Xie, Guangan He, Zahid Hussain Siddik · 2016 · Molecular Cancer Research
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Julia Abramowitz, Tzahi Neuman, Riki Perlman, Dina Ben‐Yehuda · 2017 · BMC Medical Genomics
Loss of Both CDKN2A and CDKN2B Allows for Centrosome Overduplication in Melanoma
Shyamal Patel, Christopher J. Wilkinson, Elena V. Sviderskaya · 2020 · Journal of Investigative Dermatology
Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival
M Fang, Iva Simeonova, Boris Bardot, Vincent Lejour, Sara Jaber, Rachida Bouarich-Bourimi, Aurélie Morin, Franck Toledo · 2013 · Oncogene
MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
Renier C. Heijkants, Amina F.A.S. Teunisse, Daniëlle de Jong, Kseniya Glinkina, Hailiang Mei, Szymon M. Kiełbasa, Károly Szuhai, Aart G. Jochemsen · 2022 · Cancers
TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
Safir Ullah Khan, Zahid Ullah, Hadia Shaukat, Shiza Unab, Saba Jannat, Waqar Ali, Amir Ali, Muhammad Irfan, Muhammad Fiaz Khan, Rodolfo Daniel Cervantes‐Villagrana · 2023 · Cancer Informatics
Advancements in Stapled Peptide Drug Discovery & Development
Vincent Guerlavais, Tomi K. Sawyer · 2014 · Annual reports in medicinal chemistry
Searching for Dual Inhibitors of the MDM 2‐p53 and MDMX ‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach
Andrey V. Zaytsev, Barry Dodd, Matteo Magnani, Chiara Ghiron, Bernard T. Golding, Roger J. Griffin, Junfeng Liu, Xiaohong Lü, Iolanda Micco, David R. Newell et al. · 2014 · Chemical Biology & Drug Design
RETRACTED: Downregulation of microRNA‐23b protects against ischemia‐reperfusion injury via p53 signaling pathway by upregulating MDM4 in rats
Zhihe Zhao, Jianzhong Guan, Min Wu, Guihua Lai, Zhonglian Zhu · 2018 · Journal of Cellular Biochemistry · Retracted
Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties
Rossella Lucà, Maria Rita Assenza, Fabio Maiullari, Luisa Pieroni, Silvia Maiullari, Giulia Federici, Federica Marini, Roberto Rizzi, Andrea Urbani, Silvia Soddu et al. · 2021 · Cell Death and Disease
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
Mitsuaki Hirose, Kenji Yamato, Shinji Endo, Rie Saito, Takunori Ueno, Sachiko Hirai, Hideo Suzuki, Masato Abei, Yukikazu Natori, Ichinosuke Hyodo · 2014 · Oncoscience
Circular RNA CCDC66 Improves Murine Double Minute 4 (MDM4) Expression through Targeting miR-370 in Colorectal Cancer
Yang Mo, Qin Lu, Qi Zhang, Jie Chen, Youming Deng, Ke Zhang, Ran Tao, Weidong Liu, Yiming Wang · 2022 · Computational and Mathematical Methods in Medicine
Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin
Yu Feng, Hongjie Huo, Qiong Tang · 2022 · Journal of Oncology